Nothing Special   »   [go: up one dir, main page]

PL2418201T3 - Polimorficzne postaci p-hydroksybeznoesanu (2S)-(4E)-N-metylo-5-[3-(5-izopropoksypirydyn)ylo]-4-penteno-2-aminy do leczenia zaburzeń ośrodkowego układu nerwowego - Google Patents

Polimorficzne postaci p-hydroksybeznoesanu (2S)-(4E)-N-metylo-5-[3-(5-izopropoksypirydyn)ylo]-4-penteno-2-aminy do leczenia zaburzeń ośrodkowego układu nerwowego

Info

Publication number
PL2418201T3
PL2418201T3 PL11167528T PL11167528T PL2418201T3 PL 2418201 T3 PL2418201 T3 PL 2418201T3 PL 11167528 T PL11167528 T PL 11167528T PL 11167528 T PL11167528 T PL 11167528T PL 2418201 T3 PL2418201 T3 PL 2418201T3
Authority
PL
Poland
Prior art keywords
isopropoxypyridin
penten
hydroxybenzoate
amine
methyl
Prior art date
Application number
PL11167528T
Other languages
English (en)
Inventor
Julio A Munoz
Gary Maurice Dull
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PL2418201T3 publication Critical patent/PL2418201T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL11167528T 2006-05-09 2007-05-08 Polimorficzne postaci p-hydroksybeznoesanu (2S)-(4E)-N-metylo-5-[3-(5-izopropoksypirydyn)ylo]-4-penteno-2-aminy do leczenia zaburzeń ośrodkowego układu nerwowego PL2418201T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74682106P 2006-05-09 2006-05-09
EP07783431A EP2021326A1 (en) 2006-05-09 2007-05-08 Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders
EP11167528.6A EP2418201B1 (en) 2006-05-09 2007-05-08 Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin) yl]-4-penten-2-amine p-hydroxybenzoate for the treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
PL2418201T3 true PL2418201T3 (pl) 2014-07-31

Family

ID=38441430

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11167528T PL2418201T3 (pl) 2006-05-09 2007-05-08 Polimorficzne postaci p-hydroksybeznoesanu (2S)-(4E)-N-metylo-5-[3-(5-izopropoksypirydyn)ylo]-4-penteno-2-aminy do leczenia zaburzeń ośrodkowego układu nerwowego

Country Status (29)

Country Link
US (3) US8461344B2 (pl)
EP (2) EP2418201B1 (pl)
JP (1) JP4477097B2 (pl)
KR (1) KR20090005369A (pl)
CN (1) CN101472893A (pl)
AR (1) AR060786A1 (pl)
AU (1) AU2007249485B2 (pl)
BR (1) BRPI0709781A2 (pl)
CA (1) CA2649961A1 (pl)
DK (1) DK2418201T3 (pl)
EC (1) ECSP088876A (pl)
ES (1) ES2460919T3 (pl)
HR (1) HRP20140385T1 (pl)
IL (1) IL194833A0 (pl)
MX (1) MX2008013982A (pl)
MY (1) MY144132A (pl)
NO (1) NO20084567L (pl)
NZ (1) NZ597177A (pl)
PL (1) PL2418201T3 (pl)
PT (1) PT2418201E (pl)
RS (1) RS53286B (pl)
RU (1) RU2440984C2 (pl)
SA (1) SA07280230B1 (pl)
SI (1) SI2418201T1 (pl)
TW (1) TWI389889B (pl)
UA (1) UA96447C2 (pl)
UY (1) UY30330A1 (pl)
WO (1) WO2007134034A1 (pl)
ZA (1) ZA200809284B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
WO2007134038A2 (en) * 2006-05-09 2007-11-22 Astrazeneca Ab Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
AR062860A1 (es) * 2006-09-15 2008-12-10 Astrazeneca Ab Combinaciones terapeuticas 482
EP2112923A1 (en) * 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
KR20100052490A (ko) * 2007-07-31 2010-05-19 타가셉트 인코포레이티드 (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여
US20110130428A1 (en) * 2008-06-11 2011-06-02 Astrazeneca Ab Sublingual Compositions Comprising (2S) - (4E) -N-Methyl-5- (3- (5-Isopropoxypyridin) YL)-4-Penten-2-Amine
WO2010080757A2 (en) * 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
FR2959107B1 (fr) 2010-04-23 2015-03-27 Oreal Unite d'application d'un produit cosmetique
RU2012150449A (ru) 2010-05-20 2014-06-27 Астразенека Аб Новый способ получения арилзамещенных олефиновых аминов
WO2013184732A1 (en) * 2012-06-06 2013-12-12 Targacept, Inc. Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate
KR101579904B1 (ko) 2014-09-05 2016-01-05 동신대학교산학협력단 마스카라

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192946A (en) 1978-06-29 1980-03-11 Ciba-Geigy Corporation Process for producing 3-hydroxy-5-halopyridines
DE3148651A1 (de) 1981-12-09 1983-07-21 Henkel Kgaa "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente"
US4582823A (en) 1984-08-15 1986-04-15 Warner-Lambert Company Method for treating schizophrenia and medicaments therefor
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
EP0393781B1 (en) 1989-04-20 1995-02-08 ZAMBON GROUP S.p.A. Dopamine pro-drug
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
AU9171791A (en) 1990-12-27 1992-08-17 Abbott Laboratories N-protected aminoalkylaldehydes
DE69213559T2 (de) 1991-05-30 1997-02-27 Mitsui Toatsu Chemicals Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
DE69523155T2 (de) 1994-06-14 2002-02-07 Pfizer Inc., New York Benzimidazolonderivate mit zentraler dopaminerger aktivität
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
PT900200E (pt) 1996-04-23 2009-02-26 Targacept Inc Composições farmacêuticas para prevenção e tratamento de perturbações do sitema nervoso central
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US6011159A (en) 1997-05-08 2000-01-04 Pfizer Inc Processes and intermediates for preparing substituted indazole derivatives
AU744539B2 (en) 1997-10-27 2002-02-28 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DK1086082T3 (da) 1998-06-16 2004-11-22 Targacept Inc Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6337351B1 (en) 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
AU5326100A (en) 1999-06-07 2000-12-28 Targacept, Inc. Pharmaceutical compositions and methods for use
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US20030026766A1 (en) 2000-04-13 2003-02-06 Mark Sanders Medicaments for treating respiratory disorders comprising formoterol and fluticasone
US6432954B1 (en) 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6743812B1 (en) 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
GB2381750A (en) 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
IL162153A0 (en) 2001-12-14 2005-11-20 Target Discovery Methods and compositions for treatment of central nervous systemdisorders
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US20040044023A1 (en) 2002-08-30 2004-03-04 Marc Cantillon Compositions and methods for treating or preventing memory impairment
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
MXPA06007213A (es) 2003-12-23 2006-08-18 Pfizer Prod Inc Combinacion terapeutica para la mejora de la cognicion y trastornos sicoticos.
US20050171088A1 (en) 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
AU2004319105A1 (en) 2004-03-29 2005-11-10 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
JP4148199B2 (ja) 2004-07-30 2008-09-10 松下電工株式会社 電気かみそり
WO2006015299A2 (en) 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
WO2007134038A2 (en) 2006-05-09 2007-11-22 Astrazeneca Ab Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
WO2007147014A2 (en) 2006-06-13 2007-12-21 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
AR062860A1 (es) 2006-09-15 2008-12-10 Astrazeneca Ab Combinaciones terapeuticas 482
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs

Also Published As

Publication number Publication date
BRPI0709781A2 (pt) 2011-07-26
RU2008148325A (ru) 2010-06-20
NO20084567L (no) 2008-12-04
CA2649961A1 (en) 2007-11-22
RS53286B (en) 2014-08-29
SA07280230B1 (ar) 2010-08-20
EP2021326A1 (en) 2009-02-11
UY30330A1 (es) 2008-10-31
US20070265314A1 (en) 2007-11-15
US20130310425A1 (en) 2013-11-21
EP2418201B1 (en) 2014-02-12
AR060786A1 (es) 2008-07-10
HRP20140385T1 (hr) 2014-06-06
TW200808726A (en) 2008-02-16
EP2418201A1 (en) 2012-02-15
JP4477097B2 (ja) 2010-06-09
WO2007134034A1 (en) 2007-11-22
CN101472893A (zh) 2009-07-01
MY144132A (en) 2011-08-15
PT2418201E (pt) 2014-04-14
JP2009531465A (ja) 2009-09-03
AU2007249485B2 (en) 2012-11-01
KR20090005369A (ko) 2009-01-13
NZ597177A (en) 2013-06-28
AU2007249485A1 (en) 2007-11-22
ZA200809284B (en) 2009-08-26
US20100048643A1 (en) 2010-02-25
RU2440984C2 (ru) 2012-01-27
TWI389889B (zh) 2013-03-21
IL194833A0 (en) 2009-08-03
UA96447C2 (ru) 2011-11-10
SI2418201T1 (sl) 2014-06-30
US8461344B2 (en) 2013-06-11
DK2418201T3 (da) 2014-05-12
ES2460919T3 (es) 2014-05-16
MX2008013982A (es) 2009-03-13
ECSP088876A (es) 2009-02-27

Similar Documents

Publication Publication Date Title
PT2418201E (pt) Formas polimorfas de (2s)-(4e)-n-metil-5-[3-(5- isopropoxipiridin)il]-4-penten-2-amina para o tratamento de distúrbios do sistema nervoso central
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
PL1833799T3 (pl) 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
ZA200608628B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
ZA200808963B (en) Compounds for the treatment of metabolic disorders
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL179609A0 (en) Imidazole variants as modulators of gaba receptor for the treatment of gi disorders
IL192852A0 (en) Compounds for the treatment of metabolic disorders
PL1841433T3 (pl) Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego
IL198912A0 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
IL197695A0 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
IL195392A0 (en) Compounds for the treatment of metabolic disorders
HK1129112A1 (en) 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders
IL198967A0 (en) Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
IL192982A0 (en) Compounds for the treatment of metabolic disorders
GB0724947D0 (en) Composition for the treatment of psychiatric disorders